Combination therapy of atorvastatin and amlodipine inhibits sympathetic nervous system activation and improves cognitive function in hypertensive rats

Circulation Journal

Volumn 76, Issue 8, 2012, Pages 1934-1941

  Kishi, Takuya ^a   Sunagawa, Kenji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Brain; Calcium channel blocker; Hypertension; Statin; Sympathetic nervous system

Indexed keywords

AMLODIPINE; ATORVASTATIN; HYDRALAZINE; MANGANESE SUPEROXIDE DISMUTASE; NORADRENALIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; HEART RATE; HIPPOCAMPUS; HYPERTENSION; MALE; MAZE TEST; MEAN ARTERIAL PRESSURE; MEDULLA OBLONGATA; NONHUMAN; NORADRENALIN URINE LEVEL; OXIDATIVE STRESS; RAT; ROSTRAL VENTROLATERAL MEDULLA;

AMLODIPINE; ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; COGNITION; DRUG THERAPY, COMBINATION; HEPTANOIC ACIDS; HIPPOCAMPUS; HYPERTENSION; MALE; NERVE TISSUE PROTEINS; PYRROLES; RATS; RATS, INBRED SHR; SUPEROXIDE DISMUTASE; SYMPATHETIC NERVOUS SYSTEM;

EID: 84864387149     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0276     Document Type: Article

References (63)

1. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: Overall findings and differences by age for 316,099 white men: Multiple Risk Factor Intervention trial Research Group. Arch Intern Med 1992; 152: 56-64.
2. Thomas F, Bean K, Guize L, Quentzel S, Argyriadis P, Benetos A. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women. Eur Heart J 2002; 23: 528-535.
3. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitors or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
4. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trail-Lipid Lowering Arm (ASCOT-LLA): A multicenter randomized controlled trial. Lancet 2003; 361: 1149-1158.
5. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicenter randomized placebo-controlled trial. Lancet 2004; 364: 685-696.
6. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomized trial. Lancet 2004; 363: 2022-2031.
7. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: A randomized controlled trial. JAMA 2004; 292: 2217-2225.
8. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimens of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trail-Blood Pressure Lowering Arm (ASCOTBPLA): A multicenter randomized controlled trial. Lancet 2005; 366: 895-906.
9. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435.
10. Sever P, Dahlof B, Poulter N, Wadel H, Beevers G, Caulfield M, et al. Potential synergy between lipid-lowering and blood-pressure lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006; 27: 2982-2998.
11. Cohn JN, Wilson DJ, Neutel J, Houston M, Weinberger MH, Grimm R Jr, et al. Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. Am J Hypertens 2009; 22: 137-144.
12. Fogari R, Preti P, Zoppi A, Lazzari P, Corradi L, Fogari E, et al. Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. Eur J Clin Pharmacol 2006; 62: 817-822.
13. Preston RA, Harvey P, Herfert O, Dykstra G, Jukema JW, Sun F, et al. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamics interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: The respond trial. J Clin Pharmacol 2007; 47: 1555-1569.
14. Grassi G, Seravalle G, Dell'oro R, Mancia G. Sympathetic mechanisms, organ damage, and antihypertensive treatment. Curr Hypertens Rep 2011; 13: 303-308.
15. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999; 34: 724-728.
16. Dampney RA. Functional organization of central pathways regulating the cardiovascular system. Physiol Rev 1994; 74: 323-364.
17. Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci 2006; 7: 335-346.
18. Hirooka Y, Kishi T, Sakai K, Shimokawa H, Takeshita A. Effect of overproduction of nitric oxide in the brain stem on the cardiovascular response in conscious rats. J Cardiovasc Pharmacol 2003; 41: S119-S126.
19. Hirooka Y, Kimura S, Nozoe M, Sagara Y, Ito K, Sunagawa K. Amlodipine-induced reduction of oxidative stress in the brain is associated with sympatho-inhibitory effects in stroke-prone spontaneously hypertensive rats. Hypertens Res 2006; 29: 49-56.
20. Hirooka Y, Sagara Y, Kishi T, Sunagawa K. Oxidative stress and central cardiovascular regulation: Pathogenesis of hypertension and therapeutic aspects. Circ J 2010; 74: 827-835.
21. Kishi T, Hirooka Y, Mukai Y, Shimokawa H, Takeshita A. Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthase in stroke-prone spontaneously hypertensive rats. J Hypertens 2003; 21: 379-386.
22. Kishi T, Hirooka Y, Kimura Y, Ito K, Shimokawa H, Takeshita A. Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats. Circulation 2004; 109: 3257-3262.
23. Kishi T, Hirooka Y, Shimokawa H, Takeshita A, Sunagawa K. Atorvastatin reduces oxidative stress in the rostral ventrolateral medulla in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 2008; 30: 1-9.
24. Kishi T, Hirooka Y, Konno S, Ogawa K, Sunagawa K. Angiotensin II type 1 receptor-activated caspase-3 through ras/mitogen-activated protein kinase/extracellular signal-regulated kinase in the rostral ventrolateral medulla is involved in sympathoexcitation in strokeprone spontaneously hypertensive rats. Hypertension 2010; 55: 291-297.
25. Kishi T, Hirooka Y, Konno S, Sunagawa K. Sympathoinhibition induced by centrally administered atorvastatin is associated with alteration of NAD(P)H oxidase and Mn superoxide dismutase activity in rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 2010; 55: 184-190.
26. Kishi T, Hirooka Y. Sympathoinhibitory effects of atorvastatin in hypertension. Circ J 2010; 74: 2552-2553.
27. Konno S, Hirooka Y, Araki S, Koga Y, Kishi T, Sunagawa K. Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 2008; 52: 555-560.
28. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornich KG, et al. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: Roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation 2005; 112: 1763-1770.
29. Kishi T, Hirooka Y, Konno S, Sunagawa K. Atorvastatin improves the impaired baroreflex sensitivity via anti-oxidant effect in the rostral ventrolateral medulla of SHRSP. Clin Exp Hypertens 2009; 31: 698-704.
30. Siddiqi L, Joles JA, Oey PL, Blankestijn PJ. Atorvastatin reduced sympathetic activity in patients with chronic kidney disease. J Hypertens 2011; 29: 2176-2180.
31. Sinski M, Lewandowsk J, Ciarka A, Bidiuk J, Abramczyk P, Dobosiewicz A, et al. Atorvastatin reduced sympathetic activity and increases baroreceptor reflex sensitivity in patients with hypercholesterolemia and systemic arterial hypertension. Kardiol Pol 2009; 67: 613-620.
32. Gomes ME, Tack CJ, Verheugt FW, Smits P, Lenders JW. Sympathoinhibition by atorvastatin in hypertensive patients. Circ J 2010; 74: 2622-2626.
33. Meyer JS, Rauch G, Rauch RA, Haque A. Risk factors for cerebral hypoperfusion, mild cognitive impairment, and dementia. Neurobiol Aging 2000; 21: 161-169.
34. Grande LJ, Rudolph JL, Milberg WP, Barber CE, McGlinchey RE. Detecting cognitive impairment in individuals at risk for cardiovascular disease: The "Clock-in-the-Box" screening test. Int J Geriatr Psychiatry 2011; 26: 969-975.
35. Summers MJ, Oliver KR, Coombes JS, Fassett RG. Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial. Pharmacotherapy 2007; 27: 183-190.
36. Testa MA, Tumer RR, Simonson DC, Krafcik MB, Calvo C, Luque-Otero M. Quality of life and calcium channel blockade with nifedipine GITS versus amlodipine in hypertensive patients in Spain: Gastrointestinal therapeutic System. J Hypertens 1998; 16: 1839-1847.
37. Berr C, Balansard B, Arnaud J, Roussel AM, Alperovitch A. Cognitive decline is associated with systemic oxidative stress: The EVA study: Etude du Vieillissement Arterial. J Am Geriatr Soc 2000; 48: 1285-1291.
38. Sato H, Takahashi T, Sumitani K, Takatsu H, Urano S. Glucocorticoid generates ROS to induce oxidative injury in the hippocampus, leading to impairment of cognitive function of rats. J Clin Biochem Nutr 2010; 47: 224-232.
39. Kimura S, Saito H, Minami M, Togashi H, Nakamura N, Nemoto M, et al. Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. Toxicology 2000; 153: 167-178.
40. Morris R. Development of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984; 11: 47-60.
41. Takeda S, Sato N, Takeuchi D, Kurinami H, Shinohara M, Niisato K, et al. Angiotensin receptor blocker prevented β-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension 2009; 54: 1345-1352.
42. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22: 300-305.
43. Umeji S, Umemoto S, Itoh S, Tanaka M, Kawahara S, Fukai T, et al. Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-gamma, and aortic stiffness in hypercholesterolemia. Am J Physiol 2006; 29: H2522-H2532.
44. Umemoto S, Tanaka M, Kawahara S, Kubo M, Umeji K, Hashimoto R, et al. Calcium antagonist reduces oxidative stress by upregulating Cu/Zn superoxide dismutase in stroke-prone spontaneously hypertensive rats. Hypertens Res 2004; 27: 877-885.
45. Tsutamoto T, Sakai H, Ibe K, Yamaji M, Kawahara C, Nakae I, et al. Effect of atorvastatin vs. rosvastatin on cardiac sympathetic nerve activity in non-diabetic patients with dilated cardiomyopathy. Circ J 2011; 75: 2160-2166.
46. Tsukuda K, Mogi M, Li JM, Iwanami J, Min LJ, Sakata A, et al. Diabetes-associated cognitive impairment is improved by a calcium channel blocker, nifedipine. Hypertension 2008; 51: 528-533.
47. Hanyu H, Hirao K, Shimizu S, Iwamoto T, Koizumi K, Abe K. Favourable effects of nilvadipine on cognitive function and regional vertebral blood flow on SPECT in hypertensive patients with mild cognitive impairment. Nucl Med Commun 2007; 28: 281-287.
48. Staessen JA, Wang JG, Thijs L. Calcium-channel blockade and cardiovascular prognosis: Recent evidence from clinical outcome trials. Am J Hypertens 2002; 15: 85S-93S.
49. Wang JG, Staessen JA. Benefits of antihypertensive drug treatment in elderly patients with isolated systolic hypertension. Neth J Med 2001; 58: 248-254.
50. Amenta F, Lanari A, Miginini F, Silverstrelli G, Traini E, Tomassoni D. Nicardipine use in cerebrovascular disease: A review of controlled clinical studies. J Neuro Sci 2009; 283: 219-223.
51. Blezer E, Nicolay K, Goldschmeding R, Koomans H, Joles J. Reduction of cerebral injury in stroke-prone spontaneously hypertensive rats by amlodipine. Eur J Pharmacol 2002; 444: 75-81.
52. Sakurai-Yamashita Y, Harada N, Niwa M. Lercanidipine rescues hippocampus pyramidal neurons from mild ischemia-induced delayed neuronal death in SHRSP. Cell Mol Neurobiol 2011; 31: 561-567.
53. Fukuo K, Yang J, Suzuki T, Kaimoto T, Takemura Y, Yasuda O, et al. Nifedipine upregulates manganese superoxide dismutase expression in vascular smooth muscle cells via endothelial cell-dependent pathways. Hypertens Res 2003; 26: 503-508.
54. Kishi T. Mevalonate pathway is a novel target for hypertension. Circ J 2011; 75: 1318-1319.
55. Toma L, Stancu CS, Sanda GM, Sima AV. Anti-oxidant and antiinflammatory mechanisms of amlodipine action to improve endothelial cell dysfunction induced by irreversible glycated LDL. Biochem Biophys Res Commun 2011; 22: 202-207.
56. Lenasi H, Kohlstedt K, Fichtlscherer B, Mulsch A, Busse R, Fleming I. Amlodipine activates the endothelial nitric oxide synthase by altering phosphorylation on Ser1177 and Thr495. Cardiovasc Res 2003; 59: 844-853.
57. Benito-Leon J, Louis ED, Vega S, Bermelo-Pareja F. Statins and cognitive functioning in the elderly: A population-based study. J Alzheimers Dis 2010; 21: 95-102.
58. Trompet S, van Vilet P, de Craen AJ, Jolles J, Buckley BM, Murphy MB, et al. Pravastatin and cognitive function in the elderly: Results of the PROSPER study. J Neurol 2010; 257: 85-90.
59. Bachmeier C, Beaulieu-Abdelahad D, Mullan M, Paris D. Selective dihydropyridine compounds facilitate the clearance of β-amyloid across the blood-brain barrier. Eur J Pharmacol 2011; 659: 124-129.
60. Zamorano J, Erdine S, Pavia AP, Kim JH, Al-Khadra A, Westergaard M, et al. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: The CRUCIAL trial. Curr Med Res Opin 2011; 27: 821-833.
61. Derosa G, Maffloli P. Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients. Expert Rev Cardiovasc Ther 2010; 8: 835-843.
62. Curran MP. Amlodipine/Atorvastatin: A review of its use in the treatment of hypertension and dyslipidemia and the prevention of cardiovascular disease. Drugs 2010; 70: 191-213.
63. De Bundel D, Demaegdt H, Lahoutte T, Caveliers V, Kersemans K, Ceulemans AG, et al. Involvement of the AT1 receptor subtype in the effects of angiotensin IV and LV haemorphin 7 on hippocampal neurotransmitter levels and spatial working memory. J Neurochem 2010; 112: 1223-1234.